Matthew Grist

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Peter Ballard, James Yates, Zhenfan Yang et al. · Clinical Cancer Research · 2016 · 704 citations

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 590 citations · Full text

Genetics, Pathology, Clinical Candidate +18

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 257 citations · Full text

Covalent Inhibitors, Drug Target, Thiol Reactivity +19

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson et al. · Journal of Medicinal Chemistry · 2017 · 78 citations · Full text

Synthetic studies on the DEF-rings of FR182877 and hexacyclinic acid

Paul A. Clarke, Matthew Grist, Mark R. Ebden et al. · Tetrahedron · 2004 · 30 citations

Engineering, Heterocyclic, Synthetic Studies +5